Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis

To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.Economic evaluation using a cohort model from the perspective of healthcare providers.England.People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system;...